Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ketone Esters on Liver Fat in MASLD and Obesity
NCT07097506Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Intrahepatic triglyceride content at 6 weeks and Insulin sensitivity at 6 weeks. Started Sep 2025; status: recruiting.
02
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)obesity
Beyond the preview
Go deeper on NCT07097506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097506.